ICYMI - Our CEO, Shaun Bagai, hosted a fireside chat to discuss the momentum of RenovoRx’s commercialization efforts for its RenovoCath device including an update on initial revenues generated & progress on the Ph.III TIGeR-PaC clinical trial. bit.ly/4ho4dbE $RNXT

Tune-in today, April 10th at 3:30 p.m. ET for RenovoRx CEO Shaun Bagai's presentation at the LD Micro Invitational XV: New York 2025 conference. Register for the webcast here: bit.ly/4cvTfQA $RNXT

Thank you to all who visited the RenovoRx booth at #SIR25NASH! Congratulations to our Chief Medical Officer, Ramtin Agah, MD, and his co-authors, whose research was recognized during the JVIR Award-Winning Paper Scientific Session. Read the paper here: bit.ly/42CSHVs

Proudly Made in America: RenovoRx is increasing U.S. production of its RenovoCath catheter-based device in order to meet increased demand for the targeted delivery of diagnostic &/or therapeutic agents from oncologists & interventional radiologists. bit.ly/42OE0yA $RNXT

We are proud to support #PanCANPurpleStride! RenovoRx is committed to improving the standard of care in treatment for patients diagnosed with #pancreaticcancer. Check out one of nearly 60 PanCAN events nationwide taking place this Saturday, April 26, 2025, or donate at

.Johns Hopkins Medicine has now initiated enrollment of patients with LAPC in RenovoRx's Ph III TIGeR-PaC clinical trial, becoming the newest addition to a distinguished network of clinical cancer sites across the U.S. participating in this important trial bit.ly/3YQGXfM $RNXT

“We are pleased that Johns Hopkins Medicine has been initiated to begin enrollment in our ongoing Ph. III TIGeR-PaC clinical trial,” said Leesa Gentry, Chief Clinical Officer. RenovoRx expects to achieve full enrollment in the TIGeR-PaC trial during 2025. bit.ly/3YQGXfM $RNXT

RenovoRx today announced it will host its first quarter 2025 financial results conference call on May 15th, 2025, at 4:30 p.m. ET. For details: bit.ly/4iITUj2 $RNXT

Our team is looking forward to attending and exhibiting at the 2025 Annual Pancreas Club Meeting this weekend. Stop by to learn about the latest innovations in targeted therapeutic delivery. Set up a meeting with our team at [email protected]. Let’s connect at Pancreas Club!

RenovoRx will host a dinner and discussion on innovations in drug delivery with Muneeb Ahmed, MD and Rajiv Biswal, MD at on Friday, May 16th during the 2025 Annual GEST Conference. RSVP at renovorx.com/gest

RenovoRx today announced that it has received an Issue Notification from the U.S. Patent and Trademark Office (USPTO) indicating that U.S. patent NO. 12,290,564, becomes effective today, May 6, 2025. For details: bit.ly/4jC1kWt $RNXT

"The issuance of this new patent highlights the innovation behind our TAMP therapy platform and strengthens our competitive position,” said Shaun Bagai, CEO of RenovoRx. Learn more about the expansion of RenovoRx's IP portfolio: bit.ly/4jC1kWt $RNXT

Reminder: RenovoRx will host its first quarter 2025 financial results conference call on Thursday, May 15th at 4:30 p.m. ET. For dial-in and webcast details: bit.ly/4lYaP3T $RNXT

RenovoRx CEO, Shaun Bagai, will participate in a fireside chat at the A.G.P. Virtual Healthcare Company Showcase hosted by Scott Henry, Managing Director and Healthcare Analyst at A.G.P., on May 21, 2025 at 12:40 p.m. ET. For details: bit.ly/43gdqgU $RNXT

Join us today, May 15th at 4:30 p.m. ET for RenovoRx's first quarter 2025 financial results conference call. Access the live webcast here: bit.ly/4lYaP3T $RNXT

RenovoRx today announced its financial results and business updates for the first quarter ended March 31, 2025. The Company will host a conference call today, May 15th at 4:30 p.m. ET, for details: bit.ly/3ZnChhF $RNXT

RenovoRx announced financial results and business updates for Q1 2025, highlighting RenovoCath® revenue of ~$200,000, which exceeded expectations and is anticipated to continue growing sequentially with new customer purchase orders and reorders. bit.ly/3ZnChhF $RNXT

RenovoRx will host a lunch and discussion on innovations in drug delivery with KOLs Mike Pishvaian, Dae Won Kim, MD, and Michel Ducreux, MD, PhD, on Friday, May 30th during the 2025 ASCO Annual Meeting in Chicago, IL. RSVP at renovorx.com/asco #ASCO25

RenovoRx will host a TAMP™ Peer-to-Peer Best Practices Workshop on Monday, June 23rd at 4:00 PM PT with cases presented by Dr. Bela Kis, Moffitt Cancer Center followed by a Q&A session. Register for the event by Tuesday, June 10th: bit.ly/4mRZnHE

Join us on Monday, June 23rd at 4 PM PT for a peer-to-peer best practices workshop to gain valuable insights into the TAMP™ therapy platform, enabled by the RenovoCath® device, designed for targeted locoregional therapeutic delivery. Register here: bit.ly/4mRZnHE